$ASMB
Assembly Biosciences Inc

2014 Q2 Form 10-Q Financial Statement

#000114420414030423 Filed on May 14, 2014

View on sec.gov

Income Statement

Concept 2014 Q2 2014 Q1 2013 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.410M $1.140M $1.160M
YoY Change 8.46% -1.72% -34.46%
% of Gross Profit
Research & Development $1.096M $2.974M $2.609M
YoY Change -68.77% 13.97% -59.38%
% of Gross Profit
Depreciation & Amortization $1.026K $1.266K $1.267K
YoY Change -0.08% 27.08%
% of Gross Profit
Operating Expenses $1.096M $2.974M $2.609M
YoY Change -68.77% 13.97% -59.38%
Operating Profit -$2.506M -$4.110M -$3.769M
YoY Change -47.88% 9.05% -53.98%
Interest Expense $40.00K $40.00K $50.00K
YoY Change -33.33% -20.0% 150.0%
% of Operating Profit
Other Income/Expense, Net $40.23K
YoY Change
Pretax Income -$2.470M -$4.070M -$3.720M
YoY Change -48.0% 9.41% -54.47%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$2.469M -$4.070M -$3.723M
YoY Change -48.04% 9.32% -54.45%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$525.5K -$920.8K -$1.091M
COMMON SHARES
Basic Shares Outstanding 23.40M shares 23.40M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2014 Q2 2014 Q1 2013 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $21.30M $23.60M $36.90M
YoY Change -36.42% -36.04% 18.65%
Cash & Equivalents $21.32M $23.64M $36.87M
Short-Term Investments
Other Short-Term Assets $171.6K $259.2K $200.0K
YoY Change -3.36% 29.6% -36.78%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $21.75M $23.90M $37.10M
YoY Change -35.4% -35.59% 18.22%
LONG-TERM ASSETS
Property, Plant & Equipment $7.399K $8.425K $0.00
YoY Change -20.69% -100.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $7.399K $8.425K $0.00
YoY Change -20.69% -100.0%
TOTAL ASSETS
Total Short-Term Assets $21.75M $23.90M $37.10M
Total Long-Term Assets $7.399K $8.425K $0.00
Total Assets $21.76M $23.90M $37.10M
YoY Change -35.4% -35.57% 18.19%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.421M $1.435M $1.500M
YoY Change -33.32% -4.32% -52.27%
Accrued Expenses $48.44K $27.25K $400.0K
YoY Change -89.32% -93.19% -43.66%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.500M $1.500M $2.000M
YoY Change -42.31% -25.0% -48.09%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.500M $1.500M $2.000M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $1.470M $1.462M $2.000M
YoY Change -43.15% -26.88% -48.72%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock $4.679K $23.40K
YoY Change -76.13%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $20.29M $22.44M $35.10M
YoY Change
Total Liabilities & Shareholders Equity $21.76M $23.90M $37.10M
YoY Change -35.4% -35.57% 18.19%

Cashflow Statement

Concept 2014 Q2 2014 Q1 2013 Q1
OPERATING ACTIVITIES
Net Income -$2.469M -$4.070M -$3.723M
YoY Change -48.04% 9.32% -54.45%
Depreciation, Depletion And Amortization $1.026K $1.266K $1.267K
YoY Change -0.08% 27.08%
Cash From Operating Activities -$2.320M -$5.185M -$4.370M
YoY Change -31.36% 18.65% -28.24%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $2.589K $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 -$2.589K $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $20.80M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 $1.763M $20.75M
YoY Change -91.5% 11383.79%
NET CHANGE
Cash From Operating Activities -2.320M -$5.185M -$4.370M
Cash From Investing Activities 0.000 -$2.589K $0.00
Cash From Financing Activities 0.000 $1.763M $20.75M
Net Change In Cash -2.320M -$3.425M $16.38M
YoY Change -31.56% -120.9% -377.29%
FREE CASH FLOW
Cash From Operating Activities -$2.320M -$5.185M -$4.370M
Capital Expenditures $0.00 $2.589K $0.00
Free Cash Flow -$2.320M -$5.188M -$4.370M
YoY Change -31.16% 18.71% -28.24%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2013Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2014Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"> <b>Use of estimates:</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Significant estimates inherent in the preparation of the accompanying financial statements include the fair value of stock options and warrants granted to employees, consultants, directors, investors, licensors, placement agents and underwriters.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Additionally, the Company provides a valuation allowance for deferred income tax assets when it is considered more likely than not that all or a portion of such deferred income tax assets will not be realized.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2013Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4983126 shares
CY2014Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3814170 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2338491 shares
CY2014Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
1135000 USD
CY2014Q1 vtus Restricted Stock Expensed Percentage
RestrictedStockExpensedPercentage
0.25 pure
CY2014Q1 vtus Proceeds From Sale Of Common Stock At Net Of Offering Costs
ProceedsFromSaleOfCommonStockAtNetOfOfferingCosts
1763000 USD
CY2014Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
23636722 USD
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
27061268 USD
CY2014Q1 us-gaap Other Assets Current
OtherAssetsCurrent
259194 USD
CY2013Q4 us-gaap Other Assets Current
OtherAssetsCurrent
63672 USD
CY2012Q1 vtus Shelf Registration Offering Amount
ShelfRegistrationOfferingAmount
100000000 USD
CY2014Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y
CY2014Q1 us-gaap Preferred Stock Conversion Basis
PreferredStockConversionBasis
A preferred stock is convertible into 10 common shares of the Companys common stock at any time at the holders option.
CY2014Q1 us-gaap Assets Current
AssetsCurrent
23895916 USD
CY2013Q4 us-gaap Assets Current
AssetsCurrent
27124940 USD
CY2014Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
8425 USD
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7102 USD
CY2014Q1 us-gaap Assets
Assets
23904341 USD
CY2013Q4 us-gaap Assets
Assets
27132042 USD
CY2014Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1435200 USD
CY2013Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2614619 USD
CY2014Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
27249 USD
CY2013Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
23435 USD
CY2014Q1 us-gaap Liabilities
Liabilities
1462449 USD
CY2013Q4 us-gaap Liabilities
Liabilities
2638054 USD
CY2014Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2014Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2013Q4 us-gaap Preferred Stock Value
PreferredStockValue
220 USD
CY2014Q1 us-gaap Common Stock Value
CommonStockValue
23396 USD
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
20734 USD
CY2014Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
137842936 USD
CY2013Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
135827557 USD
CY2014Q1 vtus Common Stock Value Issuable
CommonStockValueIssuable
368750 USD
CY2013Q4 vtus Common Stock Value Issuable
CommonStockValueIssuable
368750 USD
CY2014Q1 us-gaap Development Stage Enterprise Deficit Accumulated During Development Stage
DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage
115793190 USD
CY2013Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
17055572 shares
CY2014Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
22094700 shares
CY2013Q4 us-gaap Development Stage Enterprise Deficit Accumulated During Development Stage
DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage
111723273 USD
CY2014Q1 us-gaap Stockholders Equity
StockholdersEquity
22441892 USD
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
24493988 USD
CY2014Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
23904341 USD
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
27132042 USD
CY2013Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
861046 shares
CY2014Q1 vtus Class Of Warrant Or Right Grants In Period
ClassOfWarrantOrRightGrantsInPeriod
0 shares
CY2014Q1 vtus Class Of Warrant Or Right Exercised In Period
ClassOfWarrantOrRightExercisedInPeriod
0 shares
CY2014Q1 vtus Class Of Warrant Or Right Expired In Period
ClassOfWarrantOrRightExpiredInPeriod
-104867 shares
CY2014Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
756179 shares
CY2014Q1 vtus Class Of Warrant Or Right Exercisable
ClassOfWarrantOrRightExercisable
756179 shares
CY2013Q4 vtus Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights
7.77
CY2014Q1 vtus Class Of Warrant Or Right Grants In Period Weighted Average Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightGrantsInPeriodWeightedAverageExercisePriceOfWarrantsOrRights
0
CY2014Q1 vtus Class Of Warrant Or Right Expired In Period Weighted Average Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightExpiredInPeriodWeightedAverageExercisePriceOfWarrantsOrRights
0
CY2014Q1 vtus Class Of Warrant Or Right Expirations In Period Weighted Average Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightExpirationsInPeriodWeightedAverageExercisePriceOfWarrantsOrRights
6.60
CY2014Q1 vtus Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights
7.93
CY2014Q1 vtus Class Of Warrant Or Right Exercisable Weighted Average Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightExercisableWeightedAverageExercisePriceOfWarrantsOrRights
7.93
CY2014Q1 vtus Share Based Compensation Arrangement By Share Based Payment Award Option Vested And Expected To Vest Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionVestedAndExpectedToVestGranted
613500 shares
CY2014Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2682991 shares
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2069491 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.87
CY2014Q1 vtus Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Granted Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice
3.81
CY2014Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.26
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
USD
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
USD
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
USD
CY2014Q1 us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0230 pure
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.5129 pure
CY2014Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2014Q1 vtus Future Stock Based Compensation Expense Year Two
FutureStockBasedCompensationExpenseYearTwo
706326 USD
CY2014Q1 vtus Future Stock Based Compensation Expense Year Three
FutureStockBasedCompensationExpenseYearThree
619440 USD
CY2014Q1 vtus Future Stock Based Compensation Expense Year Four
FutureStockBasedCompensationExpenseYearFour
542500 USD
CY2014Q1 vtus Future Stock Based Compensation Expense Total
FutureStockBasedCompensationExpenseTotal
63500 USD
CY2014Q1 vtus Future Stock Based Compensation Expense Year Five
FutureStockBasedCompensationExpenseYearFive
1931766 USD
CY2014Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2013Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2014Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2013Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2014Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2013Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
220000 shares
CY2014Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2013Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
220000 shares
CY2014Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2014Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
23396259 shares
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
20733895 shares
CY2014Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
23396259 shares
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20733895 shares
CY2014Q1 us-gaap Share Based Compensation
ShareBasedCompensation
253813 USD
CY2014Q1 vtus Proceeds From Sale Of Common Stock At Net Of Offering Costs
ProceedsFromSaleOfCommonStockAtNetOfOfferingCosts
1763104 USD
CY2014Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
253813 USD
CY2014Q1 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
904 USD
CY2014Q1 vtus Common Stock Issuable Shares
CommonStockIssuableShares
125000 shares
CY2013Q4 vtus Common Stock Issuable Shares
CommonStockIssuableShares
125000 shares
CY2013Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2609103 USD
CY2014Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2973690 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
77046174 USD
CY2013Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1159865 USD
CY2014Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1136461 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
25298563 USD
CY2013Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3768968 USD
CY2014Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-4110151 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-102344737 USD
CY2013Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
45873 USD
CY2014Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
40234 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
402373 USD
CY2013Q1 us-gaap Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
0 USD
CY2014Q1 us-gaap Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
0 USD
us-gaap Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
6001496 USD
CY2013Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
0 USD
CY2014Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
0 USD
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
2865758 USD
CY2013Q1 us-gaap Interest Expense Other
InterestExpenseOther
0 USD
CY2014Q1 us-gaap Interest Expense Other
InterestExpenseOther
0 USD
us-gaap Interest Expense Other
InterestExpenseOther
4983572 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-13850826 USD
CY2013Q1 us-gaap Net Income Loss
NetIncomeLoss
-3723095 USD
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
-4069917 USD
us-gaap Net Income Loss
NetIncomeLoss
-115793190 USD
CY2013Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.22
CY2014Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.18
CY2013Q1 us-gaap Share Based Compensation
ShareBasedCompensation
268016 USD
us-gaap Share Based Compensation
ShareBasedCompensation
10702524 USD
CY2013Q1 vtus Stock Based Compensation Expense For Services
StockBasedCompensationExpenseForServices
16574 USD
CY2014Q1 vtus Stock Based Compensation Expense For Services
StockBasedCompensationExpenseForServices
904 USD
vtus Stock Based Compensation Expense For Services
StockBasedCompensationExpenseForServices
4367321 USD
CY2013Q1 us-gaap Depreciation
Depreciation
1267 USD
CY2014Q1 us-gaap Depreciation
Depreciation
1266 USD
us-gaap Depreciation
Depreciation
43106 USD
CY2013Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
0 USD
CY2014Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
0 USD
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
3466010 USD
CY2013Q1 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
0 USD
CY2014Q1 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
0 USD
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
1087876 USD
CY2013Q1 us-gaap Other Noncash Expense
OtherNoncashExpense
0 USD
CY2014Q1 us-gaap Other Noncash Expense
OtherNoncashExpense
0 USD
us-gaap Other Noncash Expense
OtherNoncashExpense
227910 USD
CY2013Q1 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
164066 USD
CY2014Q1 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
195522 USD
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
259194 USD
CY2013Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-768815 USD
CY2014Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1175605 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1274912 USD
us-gaap Interest Paid
InterestPaid
685397 USD
CY2014Q1 dei Document Type
DocumentType
10-Q
CY2014Q1 dei Amendment Flag
AmendmentFlag
false
CY2013Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0 USD
CY2014Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
2169762 USD
CY2013Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
20754418 USD
CY2014Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1763104 USD
CY2013Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4370119 USD
CY2014Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5185061 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-84799238 USD
CY2013Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0 USD
CY2014Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2589 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
51530 USD
CY2013Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 USD
CY2014Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2589 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-51530 USD
CY2013Q1 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
20754418 USD
CY2014Q1 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
1763104 USD
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
95477378 USD
CY2013Q1 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
0 USD
CY2014Q1 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
0 USD
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
11522380 USD
CY2013Q1 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
0 USD
CY2014Q1 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
0 USD
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
5041953 USD
CY2013Q1 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
0 USD
CY2014Q1 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
0 USD
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
1431603 USD
CY2013Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
0 USD
CY2014Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
0 USD
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
2719380 USD
CY2013Q1 us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
0 USD
CY2014Q1 us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
0 USD
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
1573000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
108487490 USD
CY2013Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
16384299 USD
CY2014Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-3424546 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
23636722 USD
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
20489219 USD
CY2005Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
0 USD
CY2013Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
36873518 USD
CY2013Q1 vtus Supplemental Warrant Issued To Placement Agent And Investors In Private Placement
SupplementalWarrantIssuedToPlacementAgentAndInvestorsInPrivatePlacement
0 USD
CY2014Q1 vtus Supplemental Warrant Issued To Placement Agent And Investors In Private Placement
SupplementalWarrantIssuedToPlacementAgentAndInvestorsInPrivatePlacement
0 USD
vtus Supplemental Warrant Issued To Placement Agent And Investors In Private Placement
SupplementalWarrantIssuedToPlacementAgentAndInvestorsInPrivatePlacement
341334 USD
CY2013Q1 vtus Warrant Issued In Connection With Convertible Notes
WarrantIssuedInConnectionWithConvertibleNotes
0 USD
CY2014Q1 vtus Warrant Issued In Connection With Convertible Notes
WarrantIssuedInConnectionWithConvertibleNotes
0 USD
vtus Warrant Issued In Connection With Convertible Notes
WarrantIssuedInConnectionWithConvertibleNotes
1166989 USD
CY2013Q1 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
0 USD
CY2014Q1 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
0 USD
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
14003158 USD
CY2013Q1 us-gaap Interest Paid
InterestPaid
0 USD
CY2014Q1 us-gaap Interest Paid
InterestPaid
0 USD
CY2014Q1 dei Document Period End Date
DocumentPeriodEndDate
2014-03-31
CY2014Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2014
CY2014Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2014Q1 dei Trading Symbol
TradingSymbol
VTUS
CY2014Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
23396259 shares
CY2014Q1 dei Entity Registrant Name
EntityRegistrantName
VENTRUS BIOSCIENCES INC
CY2014Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001426800
CY2014Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2014Q1 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2014Q1 vtus Shelf Registration Common Stock Offered Amount
ShelfRegistrationCommonStockOfferedAmount
9900000 USD
vtus Preferred Stock Conversion Convertible Into Common Stock
PreferredStockConversionConvertibleIntoCommonStock
2200000 shares
CY2014Q1 vtus Shelf Registration Securities Available For Issuance Number
ShelfRegistrationSecuritiesAvailableForIssuanceNumber
75000000 shares
CY2014Q1 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
0 USD
CY2014Q1 us-gaap Stock Issued During Period Shares Share Based Compensation Forfeited
StockIssuedDuringPeriodSharesShareBasedCompensationForfeited
-269000 shares
CY2014Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
7.22
CY2014Q1 us-gaap Common Stocks Including Additional Paid In Capital
CommonStocksIncludingAdditionalPaidInCapital
75000000 USD
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
5.69

Files In Submission

Name View Source Status
0001144204-14-030423-index-headers.html Edgar Link pending
0001144204-14-030423-index.html Edgar Link pending
0001144204-14-030423.txt Edgar Link pending
0001144204-14-030423-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
v377247_10q.htm Edgar Link pending
v377247_ex31-1.htm Edgar Link pending
v377247_ex31-2.htm Edgar Link pending
v377247_ex32-1.htm Edgar Link pending
v377247_ex32-2.htm Edgar Link pending
vtus-20140331.xml Edgar Link completed
vtus-20140331.xsd Edgar Link pending
vtus-20140331_cal.xml Edgar Link unprocessable
vtus-20140331_def.xml Edgar Link unprocessable
vtus-20140331_lab.xml Edgar Link unprocessable
vtus-20140331_pre.xml Edgar Link unprocessable